These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 25879723)

  • 21. Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.
    Bäuerle T; Hilbig H; Bartling S; Kiessling F; Kersten A; Schmitt-Gräff A; Kauczor HU; Delorme S; Berger MR
    Neoplasia; 2008 May; 10(5):511-20. PubMed ID: 18472968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
    Valable S; Petit E; Roussel S; Marteau L; Toutain J; Divoux D; Sobrio F; Delamare J; Barré L; Bernaudin M
    Nucl Med Biol; 2011 Aug; 38(6):781-93. PubMed ID: 21843775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
    Muruganandham M; Lupu M; Dyke JP; Matei C; Linn M; Packman K; Kolinsky K; Higgins B; Koutcher JA
    Mol Cancer Ther; 2006 Aug; 5(8):1950-7. PubMed ID: 16928815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring therapeutic monoclonal antibodies in brain tumor.
    Ait-Belkacem R; Berenguer C; Villard C; Ouafik L; Figarella-Branger D; Beck A; Chinot O; Lafitte D
    MAbs; 2014; 6(6):1385-93. PubMed ID: 25484065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
    Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
    J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential permeability and quantitative MR imaging of a human lung carcinoma brain xenograft in the nude rat.
    Barnett PA; Roman-Goldstein S; Ramsey F; McCormick CI; Sexton G; Szumowski J; Neuwelt EA
    Am J Pathol; 1995 Feb; 146(2):436-49. PubMed ID: 7856753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
    Jain RK; Tong RT; Munn LL
    Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?
    Gerstner ER; Emblem KE; Sorensen GA
    Cancer J; 2015; 21(4):337-42. PubMed ID: 26222087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor.
    Brem SS; Zagzag D; Tsanaclis AM; Gately S; Elkouby MP; Brien SE
    Am J Pathol; 1990 Nov; 137(5):1121-42. PubMed ID: 1700617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia.
    Duggan TJ; Cai CL; Aranda JV; Beharry KD
    Exp Lung Res; 2021 Apr; 47(3):121-135. PubMed ID: 33377400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
    Gaustad JV; Simonsen TG; Smistad R; Wegner CS; Andersen LM; Rofstad EK
    BMC Cancer; 2015 Nov; 15():900. PubMed ID: 26573613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. αvß3-Integrin-Targeted Magnetic Resonance Imaging for the Assessment of Early Antiangiogenic Therapy Effects in Orthotopic Breast Cancer Xenografts.
    Kazmierczak PM; Schneider M; Habereder T; Hirner-Eppeneder H; Eschbach RS; Moser M; Reiser MF; Lauber K; Nikolaou K; Cyran CC
    Invest Radiol; 2016 Nov; 51(11):746-755. PubMed ID: 27082316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
    Kambadakone A; Yoon SS; Kim TM; Karl DL; Duda DG; DeLaney TF; Sahani DV
    AJR Am J Roentgenol; 2015 Jan; 204(1):W11-8. PubMed ID: 25539263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
    Gossmann A; Helbich TH; Mesiano S; Shames DM; Wendland MF; Roberts TP; Ferrara N; Jaffe RB; Brasch RC
    Am J Obstet Gynecol; 2000 Oct; 183(4):956-63. PubMed ID: 11035346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
    de Groot JF; Yung WK
    Cancer J; 2008; 14(5):279-85. PubMed ID: 18836331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
    Ferrara N
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment.
    Liu HL; Hsu PH; Lin CY; Huang CW; Chai WY; Chu PC; Huang CY; Chen PY; Yang LY; Kuo JS; Wei KC
    Radiology; 2016 Oct; 281(1):99-108. PubMed ID: 27192459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.
    Su YL; Rau KM
    J Thorac Oncol; 2015 Apr; 10(4):e21-2. PubMed ID: 25789840
    [No Abstract]   [Full Text] [Related]  

  • 40. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
    Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
    Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.